Arthritis, Rheumatoid Clinical Trial
Official title:
Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus
The purpose of this study is to evaluate ultrasound hands in patients with systemic lupus erythematosus.
Introduction: The systemic lupus erythematosus (SLE) is a disease with a common articular
involvement. Approximately 1-2% of patients with SLE have joint inflammation similar to
rheumatoid arthritis (RA). There are no well-designed studies of lupus arthropathy.
Primary objectives: To evaluate the ultrasonographic examination of the hands in patients
with systemic lupus erythematosus and make its correlation with examination of patients with
rheumatoid arthritis (RA) established and with clinical, serological, radiological and
functional.
Material and methods: a transversal study will be carried out on patients diagnosed with
with SLE and RA.
Clinical Instruments: count of swollen and tender joints, visual analogue scale (VAS) for
pain (0-10 cm), edema and for disease activity; disease activity (DAS 28 and SLEDAI), hand
grip strength and pinch (Jamar dynamometer and Preston Pinch Gauge); functional
questionnaires (HAQ and DASH). It will be observed the presence of "puffy hands", Raynaud's
phenomenon and presence of autoantibodies.
Radiographic instruments: evaluation of radiographs of hands and wrists according to the
Sharp score modified by van der Heijde. Ultrasonographic Instruments (quantitative and
semi-quantitative measures): synovial hyperplasia, synovial blood flow (Power Doppler), bone
erosions and cartilage. The joints that will be evaluated: radiocarpal, distal radioulnar,
first to fifth metacarpophalangeal and proximal interphalangeal. Ultrasonographic
interobserver reproducibility will be carried out in 10% of the patients. All the
examinators will be blind for each other findings. Rheumatoid factor and anti-CCP will be
investigated in RA patients. Statistical significance will be set at 5%.
;
Observational Model: Case Control, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01682512 -
Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis
|
Phase 3 | |
| Completed |
NCT00539760 -
A Phase I Rheumatoid Arthritis Study in Healthy Volunteers
|
Phase 1 | |
| Active, not recruiting |
NCT03312465 -
Anatomical Shoulder Domelock System Study
|
||
| Completed |
NCT01208181 -
A Two-Part, 12-Week Study of Etoricoxib as a Treatment for Rheumatoid Arthritis (RA) (MK-0663-107)
|
Phase 3 | |
| Completed |
NCT03254810 -
Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects
|
Phase 1 | |
| Completed |
NCT01711814 -
A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study
|
Phase 2 | |
| Completed |
NCT03315494 -
Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers
|
Phase 1 | |
| Withdrawn |
NCT03241446 -
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
|
Phase 1 | |
| Completed |
NCT02553018 -
Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe
|
Phase 3 | |
| Completed |
NCT02748785 -
MTX Discontinuation and Vaccine Response
|
Phase 4 | |
| Active, not recruiting |
NCT02260778 -
Treat-to-target in RA: Collaboration To Improve adOption and adhereNce
|
N/A | |
| Completed |
NCT02569736 -
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation
|
||
| Completed |
NCT01750931 -
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
|
Phase 2 | |
| Not yet recruiting |
NCT01154647 -
Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes
|
N/A | |
| Withdrawn |
NCT01204138 -
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA
|
Phase 2 | |
| Completed |
NCT00975130 -
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
|
Phase 3 | |
| Completed |
NCT00913458 -
Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis
|
Phase 4 | |
| Completed |
NCT00973479 -
An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy
|
Phase 3 | |
| Completed |
NCT00550446 -
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
|
Phase 2 | |
| Completed |
NCT00660647 -
Optimized Treatment Algorithm for Patients With Early Rheumatoid Arthritis (RA)
|
Phase 3 |